DNA Repair Drugs Market Volume Analysis, Business Overview and Geographical Segmentation by 2026 Appraised By Global Players 4SC AG, Artios Pharma, Johnson & Johnson Service Inc., GlaxoSmithKline plc, Genentech, Inc., Sierra Oncology Inc.

DNA can be damaged due to endogenous factors (oxidation) or exogenous factors (UV radiations or viruses), but our cell can identify and repair the damage. However, when the repairing mechanism of the cell fails, it leads to dysfunctionality or mutations in the DNA of the cell. It can also lead to abnormal growth of cells, i.e., cancer. Such irreparable damage can be treated with DNA repair drugs such as poly ADP-ribose polymerase inhibitors (PARP). PARP blocks the activity of ADP-ribose polymerase proteins, thus preventing the replication of cancer cells.

Get Exclusive Sample Report at: https://www.coherentmarketinsights.com/insight/request-sample/2617

Global DNA Repair Drugs Market Drivers

Increasing collaboration and acquisition activities are expected to boost the global DNA repair drugs market growth. For instance, in January 2017, Merck KGaA entered into a licensed agreement with Vertex Pharmaceuticals Inc., for four research developments on approaches to cancer. The reason for the partnership was to strengthen Merck’s area of DNA damage response and immuno-oncology. Furthermore, in February 2016, Onxeo, an orphan oncology therapeutics company, acquired DNA Therapeutics, a biopharmaceutical company for its DNA repairing technology for treatment of cancer. This technology consists of a signal interfering DNA molecule (siDNA), and Onxeo S.A. intends to develop this technology as a potential treatment option for cancer. Such partnerships are expected to propel the global DNA repair drugs market growth.

Moreover, frequent research and development activities are expected to propel the global DNA repair drugs market growth. For instance, in October 2018, Pfizer began conducting a trial of talazoparib drug for the treatment of triple negative breast cancer. Currently, it’s in second phase of clinical trial and it is a type of monotherapy. Furthermore, there are many other products that are in pipeline. For instance, in February 2019, BeiGene began with its clinical trials of pamiparib for the treatment of metastatic prostate cancer. The trial of pamiparib is currently in its second phase. Such key researches are expected to boost the global DNA repair drugs market growth.

Global DNA Repair Drugs Market Regional Analysis

North America is expected to hold a dominant position in the global DNA repair drugs market. Factors such as increasing research and development activities are expected to have an influence on the North America’s DNA repair drugs market growth. For instance, in 2017, Harvard Medical School and University of South Wales conducted a study on DNA repair drugs for treatment of radiation damage that causes cancer. They have discovered the mechanism that weakens the system of our cell’s capability to repair the damages. They developed a drug, which was tested on mice and the mice were successfully able to retrieve the cell functions. The successful development of such researches is expected to propel the global DNA repair drug market growth.

Ask For Discount Before Purchasing This Business Report @ https://www.coherentmarketinsights.com/insight/request-discount/2617

Global DNA Repair Drugs Market Restraints

Failure of drugs in late stages of clinical trials has hampered the global DNA repair drugs market growth. For instance, in April 2017, Veliparib, a product by AbbVie was withdrawn from both the clinical trial studies. One of the clinical trial study involved the drug’s efficacy on breast cancer and other for lung cancer. Veliparib was treated with a combination of chemotherapy for both, lung and breast cancer treatment. Both of the trials were withdrawn at its third phase. Such failures may hinder the global DNA repair drugs market growth.

High costs of drugs are expected to hinder the global DNA repair drugs market growth. Manufacturers are focused on offering a highly effective drug, thus investing more into research and development activities. This factor further adds up into final cost price of the product. For instance, a Lynparza tablet of 50 mg costs around US$ 32. Such high cost would be an obstruction in the developing regions such as Africa, Latin America, and Asia-Pacific for the global DNA repair drugs market growth.

Global DNA Repair Drugs Market Key Players

Some of the major players operating in the global DNA repair drugs market include 4SC AG, Artios Pharma, Johnson & Johnson Service Inc., GlaxoSmithKline plc, Genentech, Inc., Sierra Oncology Inc., AstraZeneca, Karyopharm Therapeutics, Jiangsu Hengrui Medicine Co., Ltd., and Merck KGaA.

Global DNA Repair Drugs Market Taxonomy

The global DNA repair drugs market is segmented on the basis of drug, application, distribution channels, and regions.

By Drug

Niraparib (Zejula)
Olaparib (Lynparza)
Rucaparib (Rubraca)
Talazoparib (Talzenna)
Others

By Application

Ovarian cancer
Fallopian tube cancer
Peritoneal cancer
Breast cancer
Gastric cancer

By Distribution Channel

Hospital pharmacies
Retail pharmacies
Online pharmacies

By Region

North America
Latin America
Europe
Asia Pacific
Middle East
Africa

Browse Research Report At: https://www.coherentmarketinsights.com/ongoing-insight/dna-repair-drugs-market-2617

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

This release was published on openPR.